Analyst consensus rating
Moleculin Biotech Analyst Rating: none
Direct answer
Moleculin Biotech's consensus rating is none.
3 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $12.00.
Forecast evidence checked October 17, 2026.
Get free Moleculin Biotech email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $0.28
- Average price target
- $12.00
- High price target
- $31.00
- Low price target
- $2.00
- Low target gap
- +613.3%
- Target upside
- +4,179.6%
- High target gap
- +10,955.6%
- Target range width
- 10,342.4%
- Consensus rating
- none
- Analysts
- 3
- Evidence date
- October 17, 2026
- Valid through
- October 24, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Moleculin Biotech?
Moleculin Biotech has a verified none consensus. The same dataset has an average price target of $12.00.
How far are Moleculin Biotech's low and high targets from the recorded price?
The low target implies +613.3%, while the high target implies +10,955.6%.
How many analysts are included in Moleculin Biotech's consensus?
The verified consensus includes 3 analysts.
How is Moleculin Biotech's target upside or downside calculated?
The average target of $12.00 is divided by the recorded price of $0.28, then one is subtracted to produce +4,179.6%. This does not guarantee a future return.
When was Moleculin Biotech's analyst forecast verified?
The data was verified on 2026-10-17. The dataset is valid through 2026-10-24.